Agata Czarnywojtek, Paweł Gut, Kamil Dyrka, Jerzy Sowiński, Nadia Sawicka-Gutaj, Katarzyna Katulska, Piotr Stajgis, Mateusz Wykrętowicz, Jakub Moskal, Jeremi Kościński, Krzysztof Pietrończyk, Patryk Graczyk, Maciej Robert Krawczyński, Ewa Florek, Ewelina Szczepanek-Parulska, Marek Ruchała, Alfio Ferlito
Glioblastoma multiforme (GBM) is the most aggressive malignant brain tumour. The average survival time for a patient diagnosed with GBM, using standard treatment methods, is several months. Authors of the article pose a direct question: Is it possible to treat GBM solely with radioactive iodine (¹³¹I) therapy without employing the sodium iodide symporter (NIS) gene? After all, NIS has been detected not only in the thyroid but also in various tumours. The main author of this article (A.C.), with the assistance of her colleagues (physicians and pharmacologists), underwent ¹³¹I therapy after prior iodine inhibition, resulting in approximately 30% reduction in tumour size as revealed by magnetic resonance imaging (MRI)...
April 22, 2024: Endokrynologia Polska